▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2503 by analyst upside · 2026-06-27
BCAX
Bicara Therapeutics Inc.
Healthcare · Market Cap $2B · P/E 0x
ANALYST PRICE TARGET
+17.1%
implied upside to consensus target
Current Price $26.87
Consensus Target $31.46
Bull Target $46.0
Bear Target $16.0
Analysts Covering 13
ANALYST CONSENSUS — BUY
Strong Buy
3
Buy
7
Hold
3
Sell
0
52-Week Low $8.57
52-Week High $27.98
YTD Return +64.0%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) N/A
Forward P/E -7.4x
EPS (TTM) $-2.83
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $8.57
52-Week High $27.98
Current Price $26.87
Bear Target $16.0
Bull Target $46.0
● Now $26.87 ● Target $31.46
TRADING DATA
Avg Volume 586K
YTD Return +64.0%
Analyst Count 13
Consensus Buy
Upside to Target +17.1%
Last Updated 2026-06-27

ANALYST SUMMARY

Bicara Therapeutics Inc. (BCAX) is currently trading at $26.87 with a Wall Street consensus price target of $31.46, implying potential upside of 17.1% over the next 12 months. 13 analysts currently cover BCAX, with a consensus rating of Buy — 77% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $46.0, while the most cautious has a target of $16.0.

BCAX operates in the Healthcare sector with a market capitalisation of $2B. The stock is up 64.0% year-to-date and is currently trading near the upper end of its 52-week range of $8.57 – $27.98.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

AVAH +16.1%
Aveanna Healthcare Holdings Inc.
$2B · P/E 7.2x · Buy
HRMY +25.1%
Harmony Biosciences Holdings, Inc.
$2B · P/E 14.3x · Buy
HCSG +7.8%
Healthcare Services Group, Inc.
$2B · P/E 24.8x · Hold
ADUS +36.9%
Addus HomeCare Corporation
$2B · P/E 17.9x · Buy
ANIP +33.4%
ANI Pharmaceuticals, Inc.
$2B · P/E 21.3x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for BCAX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Goldman Sachs — Reiterated
Neutral → Neutral 2026-05-12 Building track record
Morgan Stanley — Reiterated
Overweight → Overweight 2026-05-12 Building track record
Guggenheim ● Initiated
Buy 2026-05-11 62% win rate (8 calls)
Goldman Sachs — Reiterated
Neutral → Neutral 2026-03-31 Building track record
Wedbush reit
Outperform → Outperform 2026-03-31 Building track record
Wells Fargo — Reiterated
Equal-Weight → Equal-Weight 2026-03-31 Building track record
Citizens reit
Market Outperform → Market Outperform 2026-03-31 Building track record
HC Wainwright & Co. — Reiterated
Buy → Buy 2026-03-31 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
—
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →